These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

715 related items for PubMed ID: 24421220

  • 1. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
    Shield PW, Papadimos DJ, Walsh MD.
    Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
    [Abstract] [Full Text] [Related]

  • 2. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
    Lew M, Pang JC, Jing X, Fields KL, Roh MH.
    Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
    [Abstract] [Full Text] [Related]

  • 3. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression.
    Hafez NH, Shaaban HM.
    Turk Patoloji Derg; 2018 Oct; 34(2):143-149. PubMed ID: 29235613
    [Abstract] [Full Text] [Related]

  • 4. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study.
    El Hag MI, Ha J, Farag R, El Hag AM, Michael CW.
    Diagn Cytopathol; 2016 Sep; 44(9):731-6. PubMed ID: 27338760
    [Abstract] [Full Text] [Related]

  • 5. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.
    Sangoi AR, Shrestha B, Yang G, Mego O, Beck AH.
    Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123
    [Abstract] [Full Text] [Related]

  • 6. Mammaglobin and CRxA-01 in pleural effusion cytology: potential utility of distinguishing metastatic breast carcinomas from other cytokeratin 7-positive/cytokeratin 20-negative carcinomas.
    Ciampa A, Fanger G, Khan A, Rock KL, Xu B.
    Cancer; 2004 Dec 25; 102(6):368-72. PubMed ID: 15558786
    [Abstract] [Full Text] [Related]

  • 7. GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin.
    Wendroth SM, Mentrikoski MJ, Wick MR.
    Ann Diagn Pathol; 2015 Feb 25; 19(1):6-9. PubMed ID: 25544392
    [Abstract] [Full Text] [Related]

  • 8. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology.
    Deftereos G, Sanguino Ramirez AM, Silverman JF, Krishnamurti U.
    Am J Surg Pathol; 2015 Sep 25; 39(9):1282-9. PubMed ID: 26274030
    [Abstract] [Full Text] [Related]

  • 9. Utility of GATA3 immunohistochemistry for diagnosis of metastatic breast carcinoma in cytology specimens.
    Braxton DR, Cohen C, Siddiqui MT.
    Diagn Cytopathol; 2015 Apr 25; 43(4):271-7. PubMed ID: 25088841
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.
    Lee BH, Hecht JL, Pinkus JL, Pinkus GS.
    Am J Clin Pathol; 2002 May 25; 117(5):745-50. PubMed ID: 12090423
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
    Yang Y, Lu S, Zeng W, Xie S, Xiao S.
    Ann Diagn Pathol; 2017 Feb 25; 26():1-5. PubMed ID: 28038704
    [Abstract] [Full Text] [Related]

  • 17. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens.
    Hou Y, Shen R, Chaudhary S, Tonkovich D, Li Z.
    Ann Diagn Pathol; 2017 Oct 25; 30():21-27. PubMed ID: 28965624
    [Abstract] [Full Text] [Related]

  • 18. Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions.
    Conner JR, Cibas ES, Hornick JL, Qian X.
    Cancer Cytopathol; 2014 Aug 25; 122(8):586-95. PubMed ID: 25044880
    [Abstract] [Full Text] [Related]

  • 19. Distinguishing breast carcinoma from Müllerian serous carcinoma with mammaglobin and mesothelin.
    Kanner WA, Galgano MT, Stoler MH, Mills SE, Atkins KA.
    Int J Gynecol Pathol; 2008 Oct 25; 27(4):491-5. PubMed ID: 18753974
    [Abstract] [Full Text] [Related]

  • 20. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas.
    Liu H, Shi J, Prichard JW, Gong Y, Lin F.
    Am J Clin Pathol; 2014 May 25; 141(5):648-55. PubMed ID: 24713735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.